AN2 Therapeutics, Inc.
About AN2 Therapeutics, Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$35.2M
- Total assets
- $62.0M
- Market cap
- $137.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $56.8M
- Operating income
- -$56.8M
- Income tax
- $0
- Net income
- -$51.3M
- EPS (basic)
- $-1.72
- EPS (diluted)
- $-1.72
Balance sheet
- Total assets
- $92.1M
- Current assets
- $86.3M
- Total liabilities
- $10.2M
- Current liabilities
- $10.2M
- Shareholders’ equity
- $81.8M
Cash flow
- Operating cash flow
- -$49.3M
- Investing cash flow
- $54.6M
- Financing cash flow
- $372.0K
- Net cash flow
- $5.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $137.6M
- EPS (diluted)
- $-1.72
- Dividend yield
- 68.18%
- Shares outstanding
- 35.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 25, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $35.2M.
- Trading 29% below its 52-week high.
- Pays a dividend yielding about 68.18% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AN2 Therapeutics, Inc..
Write a review
News about AN2 Therapeutics, Inc.
News & sentiment via Polygon.io
